Endometriosis Urogenital Diseases
Conditions
Interventions
This is a two-arm, open-label, randomized controlled clinical trial with 72 participants allocated in a 1:1 ratio by electronic randomization performed after the baseline assessment using Research Ran
Sponsors
Universidade Federal do Piauí
Universidade Federal do Piauí
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: Medical diagnosis of active endometriosis confirmed by imaging (ultrasonography or magnetic resonance imaging) or by laparoscopy, regardless of subtype (peritoneal, ovarian, or deep endometriosis), with chronic pelvic pain associated with the disease; age between 18 and 50 years; voluntary agreement to participate by signing the Informed Consent Form; availability to attend the scheduled assessments and, if allocated to the intervention group, participate in supervised face-to-face MAT Pilates sessions twice weekly for 12 weeks
Exclusion criteria
Exclusion criteria: Significant physical limitations or motor disabilities that prevent performance of the proposed MAT Pilates exercises; verbal or cognitive impairment that prevents understanding of the study instructions or questionnaires; pregnancy, breastfeeding, or being less than 6 months postpartum; uncontrolled chronic systemic diseases, such as diabetes mellitus or hypertension without adequate clinical control; neurological disorders affecting motor control, such as stroke, multiple sclerosis, or Parkinson’s disease; recent surgery or significant injuries involving the spine, pelvis, gynecological region, or upper and/or lower limbs that may limit movement or interfere with the analysis of study outcomes; current or previous abdominal, pelvic, or gynecological neoplasms; use of medications that directly interfere with exercise response or cellular metabolism, according to medical judgment; other diagnosed chronic health conditions, such as autoimmune, cardiovascular, pulmonary, or rheumatologic diseases, that may constitute potential confounding factors related to systemic inflammation, pain, or functional changes; pacemaker or other implanted electrical devices, as well as extensive metallic plates or screws, constituting a technical contraindication to bioelectrical impedance analysis; previous diagnosis of severe psychiatric disorders or use of psychotropic medications that affect pain perception or motor response, such as tricyclic antidepressants or neuroleptics
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expected outcome 1: An increase in whole-body phase angle, expressed in degrees, is expected, measured by tetrapolar multifrequency bioelectrical impedance analysis using the InBody 770® device, comparing baseline and 12-week values between the intervention and control groups | — |
Secondary
| Measure | Time frame |
|---|---|
| Expected outcome 2: A reduction in pelvic pain intensity is expected, measured using the Visual Analog Scale (VAS), ranging from 0 (no pain) to 10 (worst imaginable pain), comparing baseline and 12-week values between the intervention and control groups;Expected outcome 3: An improvement in endometriosis-related quality of life is expected, represented by a reduction in the Endometriosis Health Profile-30 (EHP-30) score, transformed to a scale ranging from 0 to 100, in which higher scores indicate worse quality of life, comparing baseline and 12-week scores between the intervention and control groups;Expected outcome 4: An increase in abdominal muscle endurance is expected, assessed using the Timed Sit-up Test and expressed as the total number of valid repetitions completed within one minute, comparing baseline and 12-week results between the intervention and control groups | — |
Countries
BR
Contacts
Public ContactNayara Sousa
Universidade Federal do Piauí
Outcome results
None listed